Hypertension: Cardiac hypertrophy as a target of antihypertensive therapy

Nature Reviews Cardiology

Volumn 7, Issue 2, 2010, Pages 66-67

  Zanchetti, Alberto ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RAMIPRIL; TELMISARTAN;

ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR DISEASE; DATA ANALYSIS; DRUG EFFICACY; DRUG TARGETING; HEART VENTRICLE HYPERTROPHY; POST HOC ANALYSIS; PRIORITY JOURNAL; SHORT SURVEY; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 76449111109     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2009.229     Document Type: Short Survey

References (10)

1. verdecchia, P. et al. effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination with Ramipril Global end Point Trial and the Telmisartan Randomized Assessment study in ACe intolerant subjects with Cardiovascular Disease. Circulation 120, 1380-1389 (2009).
2. Yusuf, s. et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 358, 1547-1559 (2008).
3. Yusuf, s. et al. effects of the angiotensinreceptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 372, 1174-1183 (2008).
4. Mancia, G. et al. Reappraisal of european guidelines on hypertension management: a european society of Hypertension Task Force document. J. Hypertens. 27, 2121-2157 (2009).
5. Dahlöf, B. et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan intervention For endpoint reduction in hypertension study (LiFe): a randomised trial against atenolol. Lancet 359, 995-1003 (2002). (Pubitemid 34286536)
6. Okin, P. M. et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 292, 2343-2349 (2004).
7. Okin, P. M. et al. Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients. Ann. Intern. Med. 147, 311-319 (2007).
8. Zanchetti, A. Bottom blood pressure or bottom cardiovascular risk? How far can cardiovascular risk be reduced? J. Hypertens. 27, 1509-1520 (2009).
9. Mann, J. F. et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the OnTARGeT study): a multicentre, randomised, double-blind, controlled trial. Lancet 372, 547-553 (2008).
10. Law, M. R., Morris, J. K. & wald, n. J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 338, 1665-1683 (2009).